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Abstract  
A comprehensive systematic literature review of reproductive side effects in women 18-55 
years old treated with opioids for one month or longer for chronic non cancer pain. A search 
of seven databases including EMBASE and Medline was undertaken (October 2014 and a 
limited re-run April 2016). The search contained key words for opioids (generic and specific 
drug names) and side effects (generic and specific reproductive). Titles were screened using 
predefined criteria by a single reviewer and abstracts and full texts by two independent 
reviewers. 10,684 papers were identified and 12 full texts (cohort (one), case-control (four), 
cross-sectional (four), case series (one) and case report (two) with a maximum of 41 cases in 
one paper) were included covering three different modes of administration: oral (six), 
intrathecal (five) and transdermal (one). Amenorrhoea occurred in 23-71% of those receiving 
oral or intrathecal opioids. Decreased libido was seen in 61-100%. Out of 10 studies which 
undertook hormonal assays, only two studies showed a statistically significant decrease in 
hormone levels. This review supports the view that there is a potential relationship between 
the use of long-term opioids in women and reproductive side effects. The evidence is 
however weak and the mode of administration, duration, type and dose of opioid might 
influence associations. Though hormone levels were statistically significant in only two 
studies, women exhibited clinically important symptoms (decreased libido and altered 
menstrual cycle). Further investigation is required with larger cohorts and analysis of 
different delivery methods.  
Key words 
Women; Opioids; Chronic non cancer pain; Hypothalamic-pituitary-gonadal axis; 
Hypogonadism. 
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Introduction 
 
Chronic Non Cancer Pain (CNCP) has been defined as any painful condition lasting for three 
months or more and not associated with neoplastic disease (cancer) [12]. CNCP affects many 
people across the globe; a World Health Organisation (WHO) 15 centre study showed that 
22% of those attending primary care suffered from persistent pain, and women were more 
commonly affected than men [23]. There are many approaches to care of CNCP, including 
self-care, physical rehabilitation, psychological approaches, medications, surgical 
intervention and alternative medicine.  Patients often need a combination of these, and in 
CNCP an integrated multidisciplinary approach is commonly required [46]. In 12-13% of 
patients with CNCP opioids are prescribed [8]. Since the late 1980’s there has been a trend 
towards increased opioid prescribing for CNCP and a recent UK observational database study 
showed a 38% increase in opioid prescribing from 2002 to 2009, this is despite a Cochrane 
review showing only weak evidence for their effectiveness [6,32]. Another systematic review 
did not find any studies that compared opioid use to non-opioid therapy that lasted more than 
a year with the majority lasting less than 16 weeks [14]. 
Adverse effects are common among people taking opioids, and 80% of patients will 
experience at least one, such as constipation, somnolence, nausea, vomiting, dizziness, 
itching, dependency, tolerance, addiction and opioid induced hyperalgesia [5,22,26,44]. 
Chronic prescription opioid use in men can lead to hypogonadotrophic hypogonadism and 
decreased levels of sex hormones, particularly testosterone, leading to reproductive and 
sexual dysfunction. This is known as opioid induced androgen deficiency (OPIAD), it is 
increasing in prevalence due to greater recognition and some studies have found up to 92% of 
those men treated with opioids are affected [1,2,7,16,27,42]. In women, it is recognised that 
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illegal dependent opioid use (for instance heroin) can be associated with hypogonadism and 
reproductive dysfunction (low libido, sexual dysfunction and amenorrhoea), with menstrual 
irregularities affecting over 50% of women using illegal opioids [10,20,39,40].The picture is 
less clear in women with respect to any association with prescription opioid use. Therefore, in 
light of the fact that non-prescription opioids can cause symptoms of reproductive 
dysfunction consistent with hypothalamic-pituitary-gonadal (HPG) axis disruption 
(hypogonadism) in women, and that there is good evidence of hypogonadism in some men 
taking long-term prescribed opioids, there is a need to further investigate hypogonadism 
related to long- term prescription opioids in females [1,2,7,10,16,20,38,40]. This has been 
highlighted as an area for further research by both the British Society of Pain and in a paper 
for the American Pain Society and American Academy of Pain Medicine highlighting 
research gaps [13,44].  
The aim of this study is therefore to conduct a comprehensive systematic review of the 
published literature in relation to long-term opioid use for CNCP and possible reproductive 
dysfunction in women aged 18-55 years old, with specific focus on endocrine side effects 
relating to hypogonadism (biochemical or clinical). 
 
Methods 
 
Prior to starting, a systematic review protocol was developed that set out the methods for the 
search, inclusion/exclusion criteria and data extraction.  There was no deviation from this 
protocol. The age range of 18-55 years old was chosen to include women up to and including 
those going through the menopause, this was following a preliminary literature search that 
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revealed menopausal symptoms may be one of the potential reproductive adverse events 
affecting women associated with long-term opioids [17]. The literature on long-term opioid 
use in women and associated reproductive dysfunction was retrieved by searching 7 
databases Medline (1946-October 2014 via Ovid), EMBASE (1974-October 2014 via Ovid), 
TOXLINE (1840-October 2014 via TOXNET), PsychINFO (1806-October 2014 via NHS 
HDAS), CINAHL (1891-October 2014 via NHS HDAS), AMED (1895-October 2014 via 
NHS HDAS) and Web of Science (1950-October 2014 via Web of Science) in October 2014. 
A limited update search was performed from October 2014 to April 2016 in Medline 
(October 2014 – April 2016 via NHS HDAS) and EMBASE (October 2014-April 2016 via 
NHS HDAS), the update search was performed on a different platform due to change of 
licensing. The search consisted of 3 search strands.  Strand 1 searched for different types of 
opioid analgesics using generic terms (e.g. exp Analgesics, Opioid/ and exp Narcotics/) and 
narrow drug name terms (e.g. Alfentanil/ and alfentanil mp). This was adapted from a search 
used for a Cochrane review on the use of opioids in CNCP and is 178 lines [32]. Strand 2 
searched for adverse effects as a generic search term (e.g. safe or safety or side effect*) using 
a search strategy taken from a paper by Golder et al. which developed adverse effects search 
filters for Medline (~100% sensitivity) and EMBASE (~83% sensitivity) [21]. This was then 
adapted for use in the other databases searched. The final search strand looked at specific 
female reproductive endocrine side effects. These included conditions identified from a 
preliminary literature search, such as opioid induced hypogonadism, opioid induced androgen 
deficiency and a wide range of female reproductive health related endocrine disorders, 
including conditions such as polycystic ovarian syndrome and symptoms such as 
amenorrhoea, libido, sexual dysfunction, menopause and infertility (e.g. Menopause/, 
Infertility, Female/, Menorrhagia/) [9,34]. Hypogonadism is also associated with less specific 
symptoms including fatigue, depression, osteoporosis and weight gain, however for the 
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systematic review it was decided to focus on reproductive dysfunction specifically [42]. The 
complete search strategy for Medline can be found in appendix 1. References from relevant 
papers were tracked, and the papers examined for whether they met the inclusion/exclusion 
criteria. 
The inclusion and exclusion criteria are presented in Table 1. These were applied to the title, 
abstract and then full text.  Due to low numbers of studies identified, we did not reject any 
papers on the basis of study design. Titles were assessed by a single reviewer (EW) and the 
abstracts and full texts were reviewed by two independent reviewers (EW, and JB or YC), 
with a third reviewer arbitrating on any conflicts of opinion (KD).  
Data from the identified studies were extracted using a predefined data extraction form which 
was developed a priori and piloted by EW (available from the author on request). Quality 
assessment was undertaken using critical appraisal skills programme (CASP) forms to cover 
the wide variety of papers included. This does not give a grade for the evidence but highlights 
the limitations and strengths which will be presented with the results [15]. 
 
Results 
 
10,694 papers were identified in the initial search, and 22 papers were identified for possible 
inclusion. The majority of title screening revealed papers that were non-human studies, 
studied men or had no relevance to the question; there were 324 abstracts for review 
following title screening. Following abstract review 22 full texts were reviewed and 12 were 
included (see Figure 1); none were removed following quality assessment. An update 
identified 241 (253 prior to excluding duplicates) additional papers, of which 225 were 
excluded based on title; of the 16 abstracts remaining none were included in the review (one 
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paper men only, one discussed no side effects, one did not mention endocrine side effects, 12 
review articles and one conference abstract). 
The studies included considered a variety of methods of opioid delivery, including oral (six 
studies), intrathecal (five studies) and transdermal (one study) opioids. One cohort study, four 
case-control studies, four cross-sectional studies, one case series and two single case reports 
were included. The studies all had very small numbers of participants, with a maximum of 41 
subjects in the case arm of one of the papers. In total there were only 165 subjects included 
across all 12 studies (including 35 controls). A summary of the included papers can be seen 
in Table 2. The outcomes the papers used were either clinical outcomes (irregular 
menstruation/lack of menstruation or decreased libido) or biochemical (Leutenising hormone 
(LH), Follicle stimulating hormone (FSH), oestrodiol, progesterone, dehydroepiandrosterone 
sulphate (DHEAS), free testosterone (fT), total testosterone (TT), prolactin (PRL), sex 
hormone binding globulin (SHBG) and GnRH stimulation test measuring subsequent levels 
of LH and FSH) or both clinical and biochemical. The results will be discussed according to 
the different potential outcomes.  
Menstrual Cycle 
Ten studies looked for changes in menstrual cycle as a marker for hypogonadism and 
reproductive dysfunction. They defined this as either amenorrhoea (absent menstruation) or 
oligomenorrhoea (either an abnormally long period of time (35 days to 6 months) between 
regular menses, or less than 9 menstrual cycles in a year) [25,33,45].  
Daniell [17] undertook a case-control study which was the only paper included in the review 
that showed a statistically significant difference in the menstrual cycle pattern between those 
taking oral opioids (52% who developed non-surgical amenorrhoea) and controls (20%, 
p<0.05). The other oral opioid studies that reported data on menstrual cycles were Fraser et 
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al. [19] which was a cross-sectional study and found 23% (3/13) of women developed 
oligo/amenorrhoea following commencing opioids, and  Rhodin et al. [36] who undertook a 
case-control study and found amenorrhoea in 81% (13/16) of cases and 0% (0/6) of controls 
(no statistical analysis given). There were two case studies, both reported amenorrhoea in 
women whilst taking long-term oral opioids, Mussig et al. [30] then showed resolution of 
amenorrhoea with decreasing dose of hydromorphone and with conversion to tramadol (a less 
potent opioid) [30,35].  
Four of the papers on intrathecal opioids reported on the menstrual status of their participants 
showing oligo/amenorrhoea in 67% [1], 71% [18], 31% [31] and 47% [37] of those treated 
with opioids. In one study, the menstrual cycle irregularities that were present at the start of 
treatment resolved by 4-8 months of treatment (it was unclear from the paper if abnormal 
menstruation was an issue preceding treatment or secondary to treatment) [31]. Abs et al. [1] 
also looked at the menstrual cycle in three control patients and each of these continued to 
have a regular cycle, but no statistical analysis was made due to the small number of subjects.  
 
One study that examined eight premenopausal women using transdermal buprenorphine 
found no alteration in menstruation.  
The data across the studies suggest that 23% to 81% of women taking oral or intrathecal 
opioids may be affected by oligo/amenorrhoea [1,17–19,31,36,37]. However, those taking 
transdermal buprenorphine did not appear to suffer with this particular adverse effect [4]. 
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Libido 
 
Three papers reported on the status of libido for premenopausal women.  Wong et al. [48] 
found no statistical difference between cases and controls attending a chronic pain clinic, 
with 61% of cases taking oral opioids reporting decreased libido and 70% of controls (p = 
0.62). Roberts et al. [37] found low libido in 71% of those receiving intrathecal opioids and 
Finch et al. [18] found low libido in 100% of those commencing intrathecal treatment. Other 
studies also provided information on libido but this was not stratified for age or gender so 
could not be included in the review.  
 
Hormone Measurements 
 
All six oral opioid studies reported on hormone levels. Of the three case-control studies 
(Daniell [17], Rhodin et al. [36] and Wong et al. [48]), two [17,36] found statistically 
significant decreases in hormone levels in cases compared with controls, but levels were 
within normal ranges. Daniell [17] found differences in TT, fT, oestrodiol and DHEAS, 
whereas Rhodin et al. [36] found differences in oestrodiol, FSH, LH, post GnRH stimulation 
LH and FSH. Wong et al. [48] found a statistically significant decrease in TT when 
comparing cases and controls complaining of low libido, but otherwise no significant 
differences in hormone levels were found. Fraser et al. [19] undertook a cross-sectional study 
and found hormone levels within normal range (LH, FSH, SHBG, oestrodiol and 
progesterone). The final two oral opioid studies were case studies and found levels that were 
below normal or within the bottom end of the normal range; Mussig et al. [30] showed a 
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negative correlation of oestrodiol level with morphine plasma levels (r = -0.6, p = 0.03) as 
they withdrew hydromorphone and replaced it with tramadol (a weaker opioid) and 
reproductive dysfunction resolved [30,35]. 
Three intrathecal studies looked at hormone levels. Abs et al. [1] undertook a case-control 
study and found lower levels of hormones (LH, FSH, oestrodiol and progesterone) in cases 
compared to controls, but this did not reach statistical significance. Finch et al. [18] found 
low levels of LH, and levels at the low end of normal for oestrodiol and FSH. Kim et al. [28] 
showed two cases with low levels of TT, fT or DHEAS and the author described these 
patients as androgen deficient.  
Aurilio et al. [4] measured hormones at baseline and throughout treatment of up to 6 months 
with transdermal buprenorphine. They found no statistically significant change in hormone 
levels (LH, FSH, TT and fT) during this period.  
 
Summary of Results 
 
The results overall found that women taking oral or intrathecal long-term opioids were more 
likely to have clinical symptoms of hypogonadism and the associated hormones were either 
low or at the lower end of normal. Three out of four case-control studies found statistically 
significant differences for hormone levels between cases and controls with the fourth 
reporting that the lack of statistical significance was likely due to small numbers. However 
those receiving transdermal buprenorphine did not have symptomatic or physiological 
changes associated with hypogonadism. All the papers included in the systematic review had 
very small numbers and the evidence is of low quality. 
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Discussion 
 
The aim of this review was to identify and describe the current evidence relating to long-term 
use of opioids in women and associated reproductive side effects, particularly symptoms 
associated with hypogonadism.  
The results of the review show that in women taking long-term oral or intrathecal opioids, 
there is a potential association with reproductive dysfunction and hypogonadism. Those 
receiving transdermal buprenorphine did not show symptoms of hypogonadism. However it 
is difficult to establish whether this could be related to the route of administration, dose or the 
mode of action of buprenorphine itself. Buprenorphine can be prescribed at much lower doses 
than morphine as its equipotency ratio is 1:110-1:115 and could potentially explain the lack 
of reproductive dysfunction. Buprenorphine is pharmacologically different to other opioids as 
it is a mixed opioid agonist-antagonist and binds strongly to opioid receptors, meaning 
endogenous opioids will have more difficulty binding to receptors, this could theoretically 
have an effect on the HPG axis [47]. At clinical doses buprenorphine acts as a full µ-agonist, 
however compared with other µ-agonists (e.g. morphine and fentanyl) it has a lower risk of 
several side effects including respiratory depression and withdrawal so this could possibly be 
reflected for reproductive side effects [29]. It is important to note that only one paper 
specifically assessed transdermal buprenorphine and numbers included in the study were 
small. 
The review only found a small number of relevant papers and each paper in turn only studied 
a small sample. Less than 200 cases and only 35 controls were included in the entire review. 
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This was not likely to be due to omission of relevant studies, as the search was 
comprehensive and over 10,000 papers were identified and screened according to predefined 
criteria. The small numbers in the studies did lead to some difficulties with analysis for the 
authors of the papers. Abs et al. [1] found levels of hormones in cases that were lower than 
controls but this difference did not reach statistical significance. The authors felt this was 
probably due to low numbers (21 cases and 3 controls). The original study populations were 
already initially small, but further restricting this to only women aged 18-55 decreased the 
numbers even further. Additionally, in the case-control study by Finch et al. [18] there were 
no controls in this age group and so this had to be considered as a cross-sectional study. 
Meta-analysis could not be undertaken as numbers were too small and each paper used 
different hormone assays and measured these in different ways for outcomes, therefore 
combining them would have been inappropriate.   
One issue that could have affected these results is confounding by indication, as chronic pain 
is associated with low libido and CNCP was the reason for receiving opioids [27]. 73% of 
patients (both sexes) attending pain clinic report current sexual difficulties associated with 
their pain due to combinations of reasons including loss of interest or satisfaction, physical 
difficulty in finding a position that was comfortable and fear of exacerbating the condition 
[3]. Four case-control studies tried to account for possible confounding factors: three 
[1,36,48] of the studies controlled for chronic pain whereas the fourth did not [17]. Daniell 
[17] found statistically significant differences for both hormonal and clinical outcomes. 
However cases were recruited through public solicitation, with a financial reward and copies 
of their endocrine blood results for those taking part, which could introduce selection bias. 
The author acknowledges that controls were not well matched to those taking opioids with 
statistically significant differences in age (controls older), smoking status (controls smoked 
less), and BMI (controls weighed less), all of which are potential confounding factors which 
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could affect menstrual cycle and thereby the reliability of the results. The controls may also 
have been systematically different from the general population, as the rate of amenorrhoea 
found in controls (20%) was higher than the rate would be expected for the general 
population (3-4%) [17,45]. Women receiving intrathecal opioids seem to be the most likely to 
be affected by reproductive dysfunction, this could be due to confounding by severity (a 
subtype of confounding by indication). These women are likely to have more severe chronic 
pain as they have been referred to secondary care for intrathecal opioids and the severity 
could be related to reproductive dysfunction [8,41]. 
A technical difficultly facing all the studies relates to how and when to measure hormonal 
levels. Hormone assays present a particular difficulty in women with irregular cycles, as 
hormone levels fluctuate throughout the menstrual cycle and there are different normal ranges 
depending on the phase of the cycle. Several of the papers recognised having samples that 
were unrelated to the menstrual cycle as a limitation [4,9,17,19,30,35,36]. Aurilio et al. [4] 
did attempt to take the repeat hormonal assays at the same phase of the cycle, but despite this, 
large variations in oestrodiol levels were found between initial and follow up tests, indicating 
that this technique did not fully account for natural variations in hormones throughout the 
cycle. Other studies tried to account for hormone (LH and FSH) variability in different ways, 
either through serial samples 15 minutes apart, GnRH stimulation tests, or samples taken at 
specific times of the day [1,36,48]. Fraser et al. [19] did not attempt to time the samples to the 
menstrual cycle as they were expecting high rates of amenorrhoea due to previous findings. 
Kim et al. [28] and Finch et al. [18] do not discuss when they sampled hormone levels. As 
described above various methods were undertaken to try to account for hormonal variation 
within the cycle but none of these were completely satisfactory and limitations still existed.  
A further important consideration is whether the women are receiving other medications that 
could affect the clinical and biochemical outcomes. The particular medications of interest in 
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women would be hormonal contraception and hormone replacement therapy (HRT), as well 
as other steroid based medications. Four papers excluded women who were receiving 
hormone based medications [4,17,19,48], Rhodin (2010) described hormonal use with three 
women receiving HRT, one study excluded women receiving steroids [1], three papers did 
not discuss hormonal medications [18,28,31] and the remaining papers were case studies. 
These different approaches to hormonal medications do not seem to have had an effect on 
results, however this would be important to consider in future research.  
Generalisability may be limited as the majority of studies were set within secondary care pain 
clinics (or from cases presenting to secondary care endocrinology clinics). Five of the studies 
looked at intrathecal opioids, which are only initiated in secondary care [43]. A study within 
Europe showed that only 23% of patients with chronic pain were seen by a “pain specialist” 
and the rest were managed in primary care.  Additionally, a German study found the median 
time from pain onset to referral to secondary care pain services of 12 years [8,41]. 
Consequently these studies represent a small subset of chronic pain patients, and they are 
likely to include subjects who have had pain for longer than those presenting to general 
practice.  
The review included women aged 18-55 years old and this represents a heterogenous group 
of women which is a potential limitation, with a median age of menopause in the UK of 52 
[24]. This age range was chosen due to a preliminary literature search revealing menopause 
as a potential adverse outcome and as such we felt it was important to include the peri-
menopausal period in the studies. Three papers had a larger age range but stratified for 
menopausal status [1,37,48], four papers either stratified or only women less than 45 years 
old [17,18,30,35], with a further five papers using 50 years old as the dividing age 
[4,19,28,31,36]. The results across the papers were consistent (except for the study examining 
transdermal buprenorphine), so the inclusion of women who are potentially at all stages of 
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the menopause did not affect the results and limiting the age range to women less than 45 
years old would have limited the included papers significantly. 
 
Clinical Implications 
The evidence reviewed appears to indicate that there is a potential relationship between long-
term opioid use and hypogonadism and reproductive dysfunction in women. The studies are 
limited, but show that clinically, women may report amenorrhoea and loss of libido, both of 
which could possibly be associated with infertility. The implications of the findings from this 
systematic review are important for shared decision making, in that when discussing long-
term opioids with premenopausal women both at initiation and review, these potential 
adverse effects should be discussed. This may influence decisions about what ongoing 
analgesia might be used. Patients may also be more likely to report symptoms of reproductive 
dysfunction if they are aware there is a possible link with their medication. 
One study by Aurilio et al. [4] evaluated transdermal opioids and found that measures of 
hormone levels did not decrease. This was reflected in the clinical findings, with no patients 
reporting menstrual disorders. This compares with the studies of oral and intrathecal opioids, 
which showed decreased hormone levels that in some cases were statistically significant. It is 
important to remember that transdermal buprenorphine is not only different to the other 
opioids administered due to the route but also in the way buprenorphine works [47]. Another 
possible reason for this difference in side effects could be the equivalent dose of 
morphine/day prescribed for which there was no data from the systematic review, but 
buprenorphine patches typically deliver a much smaller dose than oral opioids.  
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The link to reproductive dysfunction does appear to be strongest in patients commencing on 
intrathecal opioids. If use of this route of administration increases in the future, it may be 
necessary to introduce sequential hormonal assays beginning pre-treatment to detect early 
changes that may precede clinical symptoms. 
 
Further Research 
 
This area requires further research to generate high quality evidence as the current evidence 
consists of studies with small numbers of patients. It would be important to ensure that 
studies had large numbers of women included. Future studies would need to be matched if 
possible for chronic pain and age. This would be ideally be done either as a secondary 
outcome in a randomised control trial (RCT) for effectiveness of opioids in CNCP, however 
RCT’s in this area are rare or as a matched cohort study specifically looking at reproductive 
side effects. It would also be important for future research in this area to conform with recent 
definitions of long-term opioid use for epidemiological research of 90 days or more opioid 
supply to provide consistency [11]. 
 
Conclusions 
To our knowledge, this is the first comprehensive systematic review of the literature 
specifically examining the reproductive side effects of long-term prescription opioids in 
women of reproductive age. This review supports the view that long-term use of opioids 
might be associated with a negative effect on women’s reproductive function and possibly 
lead to hypogonadism, however the numbers are small and the evidence is not clear. There is 
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weak evidence that this may not be a class effect and certain types of opioid or methods of 
delivery may have a different magnitude of effect or none at all. The evidence found appears 
to show women treated with opioids have levels of sex hormones that are below or at the 
bottom end of the normal range, and that there are clinically significant changes including 
decreased libido and irregular menstrual cycle that might be associated with these low 
hormone levels. The evidence from the review will help guide discussions with women when 
considering opioid analgesics and aid in shared decision making. Further work needs to be 
undertaken to account for the confounding issue of chronic pain, and whether this is a 
contributing factor to the changes noticed. The route of opioid administration, as well as type 
of drug and morphine equivalent dose also needs to be investigated with respect to any 
potential effect of developing hypogonadism. It might be that transdermal buprenorphine is 
not related to this effect, and therefore might potentially be a safer option for opioid delivery 
in premenopausal women, this area would be of interest for further research. The key to 
further research will be larger numbers of patients and controls who are matched for chronic 
pain and longer follow up periods.  
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Table and Figure Legends 
Table 1 Inclusion and Exclusion Criteria. CNCP (Chronic Non Cancer Pain) 
Figure 1 PRISMA flow chart  
Table 2 Summary of included papers – data only described for women less than 55 years old 
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Inclusion Females 18-55 years old 
Opioid use for at least one month 
CNCP 
Exclusion Non-human studies 
Methadone use for rehabilitation from illegal drug use with no CNCP 
Illegal opioid users 
Cancer pain 
Full text unavailable after contacting the author (no papers in this category) 
Systematic review/review papers 
Editorials 
Non-English if no translation available (no papers in this category) 
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Design Authors Summary of Findings Quality Assessment from CASP 
checklists. 
Intrathecal Opioids 
Abs et al., 2000 
Belgium [1] 
Case-control study.  
Setting: Pain Clinic.  
Duration of treatment: 26.6 +/- 
16.3 months.  
Sample Size: Cases N = 21 and 
controls N = 3 
Opioid: Morphine or 
Hydromorphone 
Age: 49.2 (± 11.7), 21 
premenopausal women included 
Neuroendocrine dysfunction 
(clinically and biochemically) 
following opioid use. Obvious 
difference in hormonal levels 
between case and control in 
premenopausal women but did not 
reach significance due to small 
numbers within the subgroup.  
Positives: matched for chronic pain. 
Validated questionnaire and hormone 
levels.                         
Negatives: Selection criteria not 
described. Larger numbers needed for 
statistics, no power calculation 
performed. Missing data reasons not 
described. 
Finch et al., 2000 
Australia [17]  
Case-control (No controls for 
women < 45 years old so 
considered as cross-sectional).  
Setting: Pain Clinic. Duration 
of treatment: 0.02-8 years 
(median 2.5). 
Sample Size: N = 7 
Opioid: Morphine 
Age: 38.3 (±1.5) (mean ± SEM) 
Small doses of intrathecal morphine 
have a profound effect on the HPG 
axis so patients should be 
monitored. 
Positives: selection of 30 sequential 
patients from pain clinic. 
Negatives: No control for F < 45 years 
old so no longer case-control. One time  
hormone measures. 
Roberts et 
al.,2001 
Australia [34]  
Cross-sectional Study.  
Setting: Pain Clinic. 
Duration of treatment:  
minimum 6 months. 
Sample Size: N = 15 
Opioid: Morphine, 
hydromorphone, sufentanil 
Age: 53.4 (±1.4, range 28-88), 
15 premenopausal women 
HPG axis affected but requires 
further detailed assessment. This 
should be discussed with patients. 
Positives: 80% response rate. 
Questionnaire validated.   
Negatives: Retrospective data 
collection. Scant data for 
premenopausal females. Missing data 
not explained (in reported data for 
women <50 years old, one reports 14 
women included and another 15). 
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checklists. 
Njee et al., 2004 
France [28] 
Cross-sectional Study.  
Setting: Pain Clinic. 
Duration of treatment:  54 +/- 
39.8 months (4-144). 
Sample Size: N = 10 
Opioid: Morphine 
Age: 43.8 
No evidence of permanent HPG 
suppression. Transient 
amenorrhoea, not accompanied by 
hormonal assays supportive of HPG 
suppression. 
Negatives: retrospective data collection. 
Only minor focus on endocrine side 
effects and collected via a questionnaire 
which was not described and may not 
have been validated.  
Kim et al., 2014 
United States [26]  
Case Series. Setting: Pain 
Clinic. Duration of treatment: 
12 months and 24 
months.Sample Size: N = 2 
Opioid: Morphine 
Age: 43 and 46 
 
Two female patients < 55 years old 
were both androgen deficient on 
hormone assays. Androgen 
deficiency is common in patients 
treated with intrathecal opioids for 
CNCP. 
Positives: consecutive patients recruited        
Negatives: Only two patients included 
was a cohort study but assessed as a 
case series. Questionnaire used was not 
described and may not have been 
validated. 
Oral Opioids 
Mussig et al.,  
2007 
Germany [27] 
Case Report.  
Setting: Endocrine Clinic. 
Duration of treatment: 4 months 
hydromorphone. 
Sample Size: N = 1 
Opioid: hydromorphone 
Age: 32 
Hypogonadism when receiving 
hydromorphone which resolved 
when changed onto tramadol 
Negative: Single case reported because 
of positive effect of treatment change. 
Daniell, 2008 
United States [16] 
Case-control study.  
Setting: Primary Care 
Duration of treatment: 
Minimum 1 month. 
Sample Size: Case N = 21, 
Control N = 16 
Opioid: methadone, morphine 
sulphate, oxycodone, 
Hormonal assays were 48-57% 
lower in opioid treated women (fT, 
TT, oestrodiol, LH, FSH, DHEAS) 
compared to controls. Statistically 
significant for TT, fT, oestrodiol 
and DHEAS. 
Amenorrhoea cases: 52%, 
controls:20%, p <0.05. 
Positives: No drop outs as one time 
measurement.        
Negatives: Controls not well matched 
(chronic pain, statistically different for 
BMI, smoking status and age). Results 
not split for oral or transdermal opioid 
delivery. 
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transdermal fentanyl (in two 
cases) 
Age: Cases 39.3 (±4.9 standard 
deviation) Controls 42.7 (±3.5) 
Fraser et al., 2009 
Canada [18] 
Cross-sectional Study.   
Setting: Pain Clinic.  
Duration of treatment: 5.5 years 
(+/- 3 years) 
Sample Size: N = 14 
Opioid: daily morphine-
equivalent dose 679 ± 620mg 
Age: 38.6 (± 7.2)  
Lower rate of hypogonadism than 
expected. 21% of women had 
hypogonadism. 
Positives: interviews by a single 
interviewer with a set method.                      
Negatives: hormone assays not timed to 
cycle. Single measurement. 
 
Reddy et al., 2010  
England [32] 
Case Report.  
Setting: Endocrine Clinic. 
Duration of treatment: 7 years 
Sample Size: N = 1 
Opioid: Morphine 
Age: 37 
Hypogonadism clinically and 
biochemically. 
Negative: Single case reported because 
of clinical findings. 
 
Rhodin et al.,  
2010 
Sweden [33] 
Case-control.  
Setting: Pain Clinic. 
Duration of treatment: at least 1 
year. 
Sample Size: Case N = 16, 
controls N = 6 
Opioid: methadone, morphine, 
oxycodone 
Age: 48 (32-63), split into 
women < 50 but no average age 
given 
HPG axis disruption with sexual 
disturbance and menstrual 
irregularities. 
Positives: Validated questionnaire. 
Clinical and biochemical results 
correlate. Control group had chronic 
pain. Enough power to show statistical 
significance.   
Negatives: small numbers, 3 women 
receiving opioids on HRT, 0 in control 
group. 
Wong et al.,  Case-control.  A significant decrease in fT in Positives: Matched for chronic pain               
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2011 
Canada [44] 
Setting: Pain Clinic. Defined 
chronic pain as pain for > 
6months.               
Duration of treatment : No 
minimum stated .      
Sample Size: Cases N = 30, 
controls N = 10 
Opioid: not described 
Age: 53 (28-83), included 30 
premenopausal women 
patients with low libido and a non-
significant decrease in DHEAS but 
not correlated with symptoms of 
hypogonadism. 
Negatives: Data only partly stratified 
for pre-menopausal women. Exact 
length of time on opiates not reported. 
Recall bias asked to compare current 
sexual desire to that before opiates. 
 
Transdermal Opioids 
Aurilio et al.,  
2011 Italy [3] 
Open prospective cohort study. 
Setting: pain clinic.  
Duration of treatment: 6 months 
Sample Size: N = 8  
Opioid: Buprenorphine  
Premenopausal women. Mean 
age 39.5 (26-50) 
 
No strong endocrine impairment. 
No changes in menstrual cycle 
reported and hormone levels were 
stable or increasing. 
Positives: hormone levels used as 
outcomes and six month follow up, 
repeated measures from same patient at 
four time points.                        
Negatives: small numbers, 
demographics of group not described. 
Hormone sampling not timed to cycle. 
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 318 excluded 
13 men only 
2 opioids < 1month 
18 no side effects  
28 non endocrine side 
effects 
54 non opioid paper 
10 illicit opioids 
18 non human 
155 review article 
5 letter 
3 editorial 
7 guidelines 
4 cancer pain 
1 conference abstract 
9607 excluded 
Oct 2014 – April 2016  
253 titles identified 
9947 after excluding 
duplicates 
 
340 abstracts read 
22 full text articles 
12 
10 excluded 
8 No age/sex stratified 
data 
1 opioids for < 1 month 
1 no specific side effects 
mentioned within article 
Oct 2014 
10694 titles identified 
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